JP2016210745A - Blood lipids reducing agent - Google Patents
Blood lipids reducing agent Download PDFInfo
- Publication number
- JP2016210745A JP2016210745A JP2015097490A JP2015097490A JP2016210745A JP 2016210745 A JP2016210745 A JP 2016210745A JP 2015097490 A JP2015097490 A JP 2015097490A JP 2015097490 A JP2015097490 A JP 2015097490A JP 2016210745 A JP2016210745 A JP 2016210745A
- Authority
- JP
- Japan
- Prior art keywords
- siphonaxanthin
- reducing agent
- blood lipid
- blood
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
本発明は、シフォナキサンチンを有効成分とすることを特徴とする血中脂質低減剤に関する。 The present invention relates to a blood lipid reducing agent characterized by containing siphonaxanthin as an active ingredient.
自然界には多くのカロテノイド色素が存在しており、従来よりβ−カロテンやリコピンなどが着色剤等として利用されてきた。近年その他のカロテノイド色素も様々な生理機能を有することが明らかになり、例えば、アスタキサンチンが優れた抗酸化作用等を有することや、フコキサンチンが抗糖尿作用や抗腫瘍作用を示すことが見出され、健康食品や化粧品の素材として利用されている。 Many carotenoid pigments exist in nature, and β-carotene, lycopene, and the like have been conventionally used as colorants and the like. In recent years, it has become clear that other carotenoid pigments also have various physiological functions. For example, it has been found that astaxanthin has an excellent antioxidant action, etc., and fucoxanthin has an anti-diabetic action and an anti-tumor action. It is used as a material for health foods and cosmetics.
シフォナキサンチン（Ｃ４０Ｈ５６Ｏ６、分子量６３２.８）は、下記式（１）に示される供役二重結合に供役したケトカルボニル基を持つ特殊な分子構造をしたカロテノイドであるが、最近、抗腫瘍作用（特許文献１）、抗糖尿病・抗肥満効果（非特許文献１）等を有することが報告されるなどその機能が注目されている。 Siphonaxanthin (C 40 H 56 O 6 , molecular weight 632.8) is a carotenoid having a special molecular structure having a ketocarbonyl group serving as a serving double bond represented by the following formula (1). Recently, it has been reported that it has an antitumor action (Patent Document 1), an anti-diabetic / anti-obesity effect (Non-Patent Document 1), etc.
しかしながら、シフォナキサンチンは、天然の緑藻類の成体中に含まれる含有量が極微量であるため、実用的な量を得るにはコストや時間がかかりすぎるという問題があり、未だ機能については十分に検討されていなかった。 However, since siphonaxanthin is contained in natural adult green algae in an extremely small amount, there is a problem that it takes too much cost and time to obtain a practical amount. It was not examined.
従って、本発明者らは、シフォナキサンチンの新たな機能性を見出すことをその課題とした。 Therefore, the present inventors made it the subject to find the new functionality of siphonaxanthin.
本発明者らは、シフォナキサンチンの新たな機能性を見出すために鋭意研究をした結果、シフォナキサンチンに血中脂質低減効果があることを見出し、本発明を完成させた。 As a result of intensive studies to find a new functionality of siphonaxanthin, the present inventors have found that siphonaxanthin has an effect of reducing blood lipid, and completed the present invention.
すなわち、本発明はシフォナキサンチンを有効成分とすることを特徴とする血中脂質低減剤である。 That is, the present invention is a blood lipid reducing agent characterized by comprising siphonaxanthin as an active ingredient.
また、本発明はシフォナキサンチンを１食あたり０.１ｍｇ以上含有することを特徴とする血中脂質低減用飲食品である。 In addition, the present invention is a food / drink for blood lipid reduction characterized by containing 0.1 mg or more of siphonaxanthin per serving.
本発明の血中脂質低減剤は、これをヒト等が摂取することにより、血中の中性脂肪および遊離脂肪酸を低減することができるため、血中の脂質が引き起こすとされている脳梗塞、心筋梗塞、動脈硬化、狭心症等の疾病を予防・治療することができる。 The blood lipid reducing agent of the present invention can reduce the neutral fat and free fatty acid in the blood by ingesting it by humans and the like, so that the cerebral infarction caused by the lipid in the blood, Diseases such as myocardial infarction, arteriosclerosis and angina can be prevented and treated.
また、本発明の血中脂質低減用飲食品は、飲食品の形態でありながらも上記血中脂質低減剤と同様の効果を有するため、上記疾病の予防・治療のために日常的に摂取するのに好適である。 Moreover, since the food / beverage products for blood lipid reduction of this invention are the form of food / beverage products and have the same effect as the said blood lipid reduction agent, they are ingested daily for the prevention and treatment of the said disease. It is suitable for.
本発明の血中脂質低減剤の有効成分であるシフォナキサンチンは、例えば、ミル、モツレミル等のミル科ミル属、ヤブレグサ等のアオサ科ヤブレグサ属、クビレズタ、センナリズタ等のイワズタ科イワズタ属、タマバロニア等のバロニア科ミドリゲ属等に属する緑藻等に含まれており、これらから抽出したものを用いることができる。シフォナキサンチンの原料としては、シフォナキサンチンの含有量が高いためミル科ミル属の緑藻が好ましく、特に培養できることから上記緑藻の中でもモツレミルが好ましい。 The siphonaxanthin, which is an active ingredient of the blood lipid reducing agent of the present invention, is, for example, a mill family such as mill, mottle, etc. It is contained in green algae and the like belonging to the genus Baroniaceae, and those extracted from these can be used. As the raw material for siphonaxanthin, green algae belonging to the genus Myraceae are preferable because of the high content of siphonaxanthin, and motremyl is preferable among the green algae because it can be cultured.
また、上記緑藻等からのシフォナキサンチンの抽出方法は、特に限定されず、特開２０１３−５１８９２号公報、特開２００９−２２７６４２号公報等に記載されている方法に従えばよい。また、緑藻等からシフォナキサンチンを抽出した後は、更に、エバポレータ等による濃縮、ＨＰＬＣ等による精製、結晶化等を行ってもよい。 Moreover, the extraction method of siphonaxanthin from the said green algae etc. is not specifically limited, What is necessary is just to follow the method described in Unexamined-Japanese-Patent No. 2013-51892, Unexamined-Japanese-Patent No. 2009-227642, etc. Moreover, after extracting siphonaxanthin from green algae etc., you may further perform concentration by an evaporator etc., purification by HPLC etc., crystallization, etc.
具体的に緑藻であるモツレミルからシフォナキサンチンを抽出するには、モツレミルをエタノール、アセトン等の有機溶剤に浸漬して粗抽出物を得て、これをダイヤイオンＨＰ２０等の合成吸着剤を用いた濃縮や減圧濃縮、分離精製を行えばよく、それによりシフォナキサンチンを高含有量で含む油状物質が得られる。この油状物質は、更にクロマトグラフィーや結晶化等で精製してもよい。また、本発明の血中脂質低減剤には、このような油状物質を利用することもできる。 Specifically, to extract siphonaxanthin from mottle mill, which is a green algae, motre mill was immersed in an organic solvent such as ethanol or acetone to obtain a crude extract, which was then used with a synthetic adsorbent such as Diaion HP20. Concentration, concentration under reduced pressure, and separation / purification may be performed, whereby an oily substance containing a high content of siphonaxanthin is obtained. This oily substance may be further purified by chromatography or crystallization. Moreover, such an oily substance can also be utilized for the blood lipid reducing agent of the present invention.
本発明の血中脂質低減剤における、シフォナキサンチンの含有量は、血中脂質低減効果が認められる量であれば特に制限されないが、例えば、シフォナキサンチンを１日あたり０.１ｍｇ以上、好ましくは１ｍｇ以上で投与されるような量である。なお、本発明の血中脂質低減剤に含有されるシフォナキサンチンの量が少ない場合、血中脂質低減効果が得られないことがある。 The content of siphonaxanthin in the blood lipid reducing agent of the present invention is not particularly limited as long as the effect of reducing blood lipid is recognized. For example, 0.1 mg or more of siphonaxanthin per day is preferable. Is such that it is administered at 1 mg or more. In addition, when the amount of siphonaxanthin contained in the blood lipid reducing agent of the present invention is small, the blood lipid reducing effect may not be obtained.
また、本発明の血中脂質低減剤には、本発明の効果を損なわない範囲で、例えば、大豆油、パーム油、中鎖脂肪酸等の油脂、結晶セルロース、デキストリン等の賦形剤、グリセリン脂肪酸エステル、レシチン等の乳化剤等の添加剤を含有させてもよい。これらの添加剤の中でも、中鎖脂肪酸等の油脂は、シフォナキサンチンを懸濁することにより酸素との接触が妨げて安定化させることができるため好ましい。 In addition, the blood lipid reducing agent of the present invention includes, for example, soybean oil, palm oil, fats and oils such as medium chain fatty acids, excipients such as crystalline cellulose and dextrin, glycerin fatty acids, and the like within the range not impairing the effects of the present invention. You may contain additives, such as emulsifiers, such as ester and a lecithin. Among these additives, oils and fats such as medium chain fatty acids are preferable because they can be stabilized by suspending siphonaxanthin to prevent contact with oxygen.
本発明の血中脂質低減剤の形態は、特に限定されず、例えば、ソフトカプセル、錠剤、乳化飲料等が挙げられる。これらの形態の中でも安定性が高いソフトカプセルや錠剤が好ましい。 The form of the blood lipid reducing agent of the present invention is not particularly limited, and examples thereof include soft capsules, tablets, and emulsified beverages. Among these forms, soft capsules and tablets having high stability are preferable.
また、本発明の血中脂質低減剤の投与方法も、特に限定されず、例えば、経口投与等が挙げられる。 Moreover, the administration method of the blood lipid reducing agent of this invention is not specifically limited, For example, oral administration etc. are mentioned.
以上説明した本発明の血中脂質低減剤は、例えば、シフォナキサンチンをヒトに１日あたり、０.１ｍｇ以上、好ましくは１ｍｇ以上を投与されるように用いて、これを継続的に摂取することにより血中の脂質、例えば、中性脂肪および遊離脂肪酸を低減することができる。 The blood lipid reducing agent of the present invention described above, for example, uses syphonaxanthin such that 0.1 mg or more, preferably 1 mg or more is administered to humans per day, and is continuously ingested. Thus, blood lipids such as neutral fat and free fatty acid can be reduced.
また、上記のようにして、本発明の血中脂質低減剤を継続的に摂取することにより、脳梗塞、心筋梗塞、動脈硬化、狭心症等の疾病を予防・治療することができる。 Moreover, diseases such as cerebral infarction, myocardial infarction, arteriosclerosis and angina can be prevented and treated by continuously ingesting the blood lipid reducing agent of the present invention as described above.
なお、本発明の血中脂質低減剤の有効成分であるシフォナキサンチンを従来公知の飲食品に含有させれば、血中脂質低減用飲食品となる。この場合、飲食品にシフォナキサンチンを１食あたり０.１ｍｇ以上、好ましくは１ｍｇ以上含有させればよい。なお、シフォナキサンチンは、緑藻に極微量しか含まれていないため、これを通常の量で食したとしても１食あたりの量は上記範囲にはならない。そのため、上記のようなシフォナキサンチンを１食あたり０.１ｍｇ以上含有するような飲食品はこれまで知られていない。 In addition, if the siphonaxanthin which is an active ingredient of the blood lipid reducing agent of this invention is contained in a conventionally well-known food / beverage product, it will become food / beverage products for blood lipid reduction. In this case, the food and drink may contain siphonaxanthin in an amount of 0.1 mg or more, preferably 1 mg or more per serving. Since siphonaxanthin contains only a trace amount in green algae, even if it is eaten in a normal amount, the amount per serving does not fall within the above range. Therefore, foods and drinks containing 0.1 mg or more of the above siphonaxanthin per meal have not been known so far.
上記飲食品の種類は、特に限定されず、例えば、清涼飲料、炭酸飲料、アルコール飲料、乳化飲料、栄養ドリンク、エナジードリンク等の飲料類、アイスクリーム、ソフトクリーム、シャーベット等の冷菓、牛乳、チーズ、ヨーグルト等の乳製品、アメ、ガム、チョコレート、グミ、せんべい、ビスケット等の菓子類、ゼリー、プリン、ヨーグルト等のデザート類、そば、うどん、そうめん、ラーメン、パスタ等の麺類、ハム、ソーセージ、かまぼこ、さつま揚げ等の加工食品類、マヨネーズ、ドレッシング、ソース等の調味料類、パン、カステラ、タルト、ケーキ、ごはん等の食品類、ソフトカプセル、錠剤、サプリメント等の健康食品類等が挙げられる。これらの飲食品の中でもソフトカプセル、錠剤、乳製品または飲料が好ましい。 The type of the food or drink is not particularly limited. For example, soft drinks, carbonated drinks, alcoholic drinks, emulsified drinks, nutrition drinks, energy drinks, and other beverages, ice cream, soft cream, sorbet and other frozen desserts, milk, cheese Dairy products such as yogurt, sweets such as candy, gum, chocolate, gummy, rice crackers, biscuits, desserts such as jelly, pudding, yogurt, noodles such as buckwheat, udon, somen, ramen, pasta, ham, sausage, Processed foods such as kamaboko and deep-fried sweet potato, seasonings such as mayonnaise, dressing and sauce, foods such as bread, castella, tart, cake and rice, and health foods such as soft capsules, tablets and supplements. Among these foods and beverages, soft capsules, tablets, dairy products or beverages are preferable.
以下、本発明を実施例を挙げて詳細に説明するが、本発明はこれら実施例に何ら限定されるものではない。 EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in detail, this invention is not limited to these Examples at all.
実 施 例 １
血中脂質低減剤の調製：
凍結乾燥したモツレミル１ｋｇを９５％エタノール２０Ｌに浸漬し、粗抽出物１８５０ｇを得た。この粗抽出物を減圧濃縮してエタノールを除去し、油状の抽出物２９２.３ｇを得た。この抽出物を合成吸着剤（ダイヤイオンＨＰ２０）に吸着させた後、エタノールで溶出させて油状のシフォナキサンチン画分を得た（シフォナキサンチンを５２質量％含有）。
Example 1
Preparation of blood lipid reducing agent:
1 kg of freeze-dried mottle mill was immersed in 20 L of 95% ethanol to obtain 1850 g of a crude extract. The crude extract was concentrated under reduced pressure to remove ethanol to obtain 292.3 g of an oily extract. This extract was adsorbed on a synthetic adsorbent (Diaion HP20) and then eluted with ethanol to obtain an oily siphonaxanthin fraction (containing 52 mass% of siphonaxanthin).
試 験 例 １
血中脂質低減試験：
糖尿病／肥満マウスであるＫＫ−Ａｙマウス（４週齢、♂、ｎ＝７）を室温２３℃で、１週間、餌、水を自由摂取させた（期間Ａ）。続いて、室温２３℃で、１週間、以下の表１に記載の試験試料、水を自由摂取させた（期間Ｂ）。期間Ａ経過後および期間Ｂ経過後に、それぞれマウスから採血し、血液中の総コレステロール、ＨＤＬコレステロール、中性脂肪、リン脂質、遊離脂肪酸の各量を測定した。それらの結果を表２に示した。
Test example 1
Blood lipid reduction test:
Diabetes / obese mice, KK-A y mice (4 weeks old, sputum, n = 7) were allowed to freely ingest food and water at room temperature of 23 ° C. for 1 week (period A). Subsequently, the test samples described in Table 1 below and water were freely ingested at room temperature of 23 ° C. for 1 week (period B). After the period A and the period B, blood was collected from each mouse, and the amounts of total cholesterol, HDL cholesterol, neutral fat, phospholipid, and free fatty acid in the blood were measured. The results are shown in Table 2.
以上の結果より、シフォナキサンチンの投与により、血中の中性脂肪および遊離脂肪酸が有意に低下することが確認された。また、総コレステロール、ＨＤＬコレステロールは上昇し、リン脂質については変化が見られなかった。 From the above results, it was confirmed that administration of siphonaxanthin significantly reduced blood neutral fat and free fatty acids. Further, total cholesterol and HDL cholesterol increased, and no change was observed in phospholipids.
実 施 例 ２
錠剤の調製：
実施例１で得た血中脂質低減剤（シフォナキサンチンを５２質量％含有）０.２ｍｇ、結晶セルロース２００ｍｇ、グリセリン脂肪酸エステル２ｍｇを混合し、打錠機で打錠して錠剤を得た（１錠あたりシフォナキサンチンを０.１ｍｇ含有）。
Example 2
Tablet preparation:
The blood lipid reducing agent (containing 52% by mass of siphonaxanthin) 0.2 mg obtained in Example 1, 200 mg of crystalline cellulose, and 2 mg of glycerin fatty acid ester were mixed, and tableted with a tableting machine to obtain tablets ( (Contains 0.1 mg of siphonaxanthin per tablet).
上記で得た錠剤を１日あたりシフォナキサンチンが０.１〜１ｍｇ程度摂取できるように服用し、これを継続することで血中脂質が低減し得る。 The tablet obtained above can be taken so that about 0.1 to 1 mg of siphonaxanthin can be taken per day, and blood lipid can be reduced by continuing this.
実 施 例 ３
飲食品の調製：
実施例１で得た血中脂質低減剤（シフォナキサンチンを５２質量％含有）０.２ｍｇを、グリセリン脂肪酸エステル１ｍｌに懸濁した後、水に乳化分散させ、更に香料および甘味料を加えて飲料を調製した（１瓶（５０ｍｌ）あたりシフォナキサンチンを０.１ｍｇ含有）。
Example 3
Preparation of food and drink:
After 0.2 mg of the blood lipid reducing agent (containing 52% by mass of siphonaxanthin) obtained in Example 1 is suspended in 1 ml of glycerin fatty acid ester, it is emulsified and dispersed in water, and flavors and sweeteners are added. A beverage was prepared (containing 0.1 mg of siphonaxanthin per bottle (50 ml)).
上記で得た飲料を１日あたりシフォナキサンチンが０.１〜１ｍｇ程度摂取できるように服用し、これを継続することで血中脂質が低減し得る。 The drink obtained above can be taken so that about 0.1 to 1 mg of siphonaxanthin per day can be taken, and blood lipid can be reduced by continuing this.
本発明の血中脂質低減剤は、これをヒト等が摂取することにより、血中の中性脂肪および遊離脂肪酸を低減することができるため、血中の脂質が引き起こすとされている脳梗塞、心筋梗塞、動脈硬化、狭心症等の疾病の予防・治療に利用することができる。
以 上
The blood lipid reducing agent of the present invention can reduce the neutral fat and free fatty acid in the blood by ingesting it by humans and the like, so that the cerebral infarction caused by the lipid in the blood, It can be used for the prevention and treatment of diseases such as myocardial infarction, arteriosclerosis and angina.
that's all
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015097490A JP2016210745A (en) | 2015-05-12 | 2015-05-12 | Blood lipids reducing agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015097490A JP2016210745A (en) | 2015-05-12 | 2015-05-12 | Blood lipids reducing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2016210745A true JP2016210745A (en) | 2016-12-15 |
Family
ID=57551230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015097490A Pending JP2016210745A (en) | 2015-05-12 | 2015-05-12 | Blood lipids reducing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2016210745A (en) |
-
2015
- 2015-05-12 JP JP2015097490A patent/JP2016210745A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| THE JOURNAL OF NUTRITION, vol. 145:490-498., JPN7018004055, 24 December 2014 (2014-12-24) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0782827B1 (en) | Use of a balancing agent for omega-6 and omega-3 unsaturated fatty acids | |
| US9492424B2 (en) | Muscle atrophy inhibitor | |
| JP5997887B2 (en) | Oral administration | |
| JPWO2015137357A1 (en) | Composition comprising sophorolipid, physiologically active substance and oil and fat, and method for producing the same | |
| JPH10155459A (en) | Astaxanthin-containing drink | |
| JP2013053109A (en) | Agent for increasing phospholipid-bound dha | |
| JPWO2005011672A1 (en) | Oil processing composition for prevention and improvement of lifestyle-related diseases | |
| JP2009269865A (en) | Oral administration agent | |
| JP2013192515A (en) | Oyster extract | |
| JPWO2019107531A1 (en) | Composition for suppressing or reducing the increase of blood lipids | |
| JP2008031076A (en) | Adiponectin production enhancer | |
| JP5000214B2 (en) | Novel compounds and osteoclast differentiation / proliferation inhibitors | |
| JP2016210745A (en) | Blood lipids reducing agent | |
| WO2015137500A1 (en) | Anti-obesity agent | |
| JP2009269864A (en) | Agent for increasing phospholipid-bound arachidonic acid | |
| JP2007051103A (en) | Antioxidant composition | |
| JP6044944B2 (en) | Process for producing new processed ume products and functional composition, food composition, and pharmaceutical composition using the same | |
| JP2005179264A (en) | Body weight gain inhibitor | |
| WO2004064830A1 (en) | Processed fat compositions for preventing and improving lifestyle-related diseases | |
| JP2009073768A (en) | New compound and osteoclast differentiation and proliferation inhibitor | |
| JP2016108242A (en) | Blood parameter improving agent | |
| JP2011236192A (en) | Food composition containing sesamin | |
| JP5479696B2 (en) | In vivo plasmalogen increasing agent | |
| JP2014185099A (en) | Cell-growth inhibitor and preventive-therapeutic agent for cancer | |
| JPWO2019172369A1 (en) | Composition for prevention or suppression of hemorrhagic angiopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180420 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190604 |